Contact Us
Drug Search Results
More Filters [+]

Indatuximab ravtansine

Alternative Names: indatuximab ravtansine, bt-062, bt062, bt 062
Latest Update: 2023-07-04
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: SDC Inhibitor

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Biotest
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Indatuximab ravtansine

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Multiple Myeloma|Transitional Cell Carcinoma|Triple Negative Breast Cancer|Bladder Cancer

Phase 1: Multiple Myeloma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
NCT01638936

P2

Completed

Multiple Myeloma

2018-10-30

53%
INTRAIN-BB (INdaTuximab RAvtansin effect IN Breast and Bladder cancer)

P2

Completed

Transitional Cell Carcinoma|Bladder Cancer|Triple Negative Breast Cancer

2017-08-04

NCT01001442

P2

Completed

Multiple Myeloma

2014-07-01

NCT00723359

P1

Completed

Multiple Myeloma

2012-04-01

Recent News Events

Date

Type

Title

07/04/2023

PubMed

 Syndecan‑1 expression is an independent favourable prognostic marker in oesophageal adenocarcinoma and represents a potential therapeutic target.

11/01/2021

PubMed

 Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study.

01/01/2021

PubMed

 Syndecans in cancer: A review of function, expression, prognostic value, and therapeutic significance.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions